An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

NCT06335979 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus, SLE

Interventions

DRUG: PIT565

Sponsor

Novartis Pharmaceuticals